Company Information

  

Address: 11388 SORRENTO VALLEY ROAD  
City: SAN DIEGO 
State: CA 
Zip Code: 92121-1345 
Telephone: (858) 794-8889 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/20180.53NA36.96
12/20170.45NA45.02
09/2017-0.67NAN/E
06/2017-0.92NAN/E
03/2017-0.91NAN/E
12/2016-0.81NAN/E
09/2016-0.55NAN/E
06/2016-0.52NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity0.09Total Liab/Total Assets0.60
Net Inc/Total Assets0.12Total Liab/Inv Cap1.00
Net Inc/Inv Cap0.20Total Liab/Comm Equity0.43
Pretax Inc/Net Sales0.19Interest Coverage Ratio3.80
Net Inc/Net Sales0.20Curr Debt/Equity0.37
Cash Flow/Net Sales0.42LTD/Equity0.60
SG&A/NetSales0.17Total Debt/Equity0.97
Asset Utilization   Liquidity  
Net Receivables Turnover16.75Quick Ratio3.85
Inventory Turnover3.15Current Ratio3.89
Inventory Day Sales0.02Net Rec/Curr Assets0.04
Net Sales/Work Cap0.84Inv/Curr Assets0.01
Net Sales/PP&E89.95  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 30.87 189.56 63.73 33.75
Cost of Goods Sold 3.05 7.49 8.33 7.79
Selling & Admin Exps 13.56 14.77 13.33 13.10
Operating Income -23.71 125.93 8.08 -25.48
Interest Exp 5.23 5.46 5.54 5.54
Pretax Income -27.27 121.55 3.33 -30.58
Other Income 1.67 1.08 0.79 0.44
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -27.46 123.88 2.75 -30.76

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 433.69 469.21 316.92 297.53
Receivables - Total 26.57 22.13 14.70 14.47
Inventories - Total 4.39 5.15 9.33 15.17
Total Current Assets 484.47 510.37 353.35 340.83
Net Property, Plant & Equipment 4.94 3.52 3.23 3.33
Total Assets 495.47 519.95 357.15 344.79
Liabilities        
Accounts Payable 35.52 47.55 36.52 32.58
Debt in Current Liabilities 82.46 77.21 61.43 45.52
Total Current Liabilities 119.22 131.33 102.05 82.62
Long-Term Debt 102.70 125.14 145.42 165.52
Total Liabilities 230.41 311.58 284.76 286.62
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.14 0.14 0.14 0.14
Retained Earnings -478.57 -522.37 -646.25 -649.00
Treasury Stock NA NA NA NA
Total Stockholders' Equity 265.06 208.37 72.39 58.17
Total Liabilities and Stockholders' Equity 495.47 519.95 357.15 344.79

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -22.18 153.25 20.26 -17.00
Net Cash Provided by Investing Activities -35.90 -148.99 30.28 -49.29
Net Cash Provided by Financing Activities -12.65 0.08 -0.89 135.85

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201354.80-83.48-0.74
12/201475.33-68.38-0.56
12/2015135.06-32.23-0.25
12/2016146.69-103.02-0.81
12/2017316.6162.970.45
Growth Rates55.04----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18233123,37485.70




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.